3rd Quarter - Report

W STRATEGIES, LLC for GENZYME CORPORATION

Period 3rd Quarter 2013 Filed Oct 21, 2013 Signed by Darren Willcox, Manager

Official filing
Firm
W STRATEGIES, LLC
Client
GENZYME CORPORATION
Income
$30,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

H.R. 1919: Safeguarding Americas Pharmaceuticals Act of 2013. S. 957: Drug Supply Chain Security Act. S. 959: Pharmaceutical Compounding Quality and Accountability Act. H.R. 3089: Compounding Clarity Act of 2013.H.R. 3024: The Drug Quality and Security Act.

LobbyistCovered position, as disclosed
DARREN WILLCOX —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 3024 (113th), S. 957 (113th), H.R. 1919 (113th), H.R. 3089 (113th), S. 959 (113th)

Medicare/Medicaid MMM

Monitored legislative efforts to reform the Sustainable Growth Rate (SGR) formula for physicians in Medicare.

LobbyistCovered position, as disclosed
DARREN WILLCOX —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.